TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1722785
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose aprotinin (2,000,000 KIU loading dose, 500,000 KIU/h infusion until skin closure, plus 2,000,000 KIU in priming volume)
Study: 1722785
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose aprotinin in risk patients (redo-operations, infective endocarditis)
Study: 1722785
Drug: Lower dosage
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dosage aprotinin (2,000,000 KIU during induction or in priming volume only)
Study: 6918343
Drug: Intravesical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical prostaglandin E2 (1.5 mg in 50 ml 0.9% NaCl)
Study: 31845865
Drug: Perindopril tert-butylamine
Normalized name: Perindopril tert-butylamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril tert-butylamine tablets
Study: 29338762
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg once weekly plus methotrexate for 36 weeks, followed by randomized treatment with etanercept 50 mg or 25 mg QW plus methotrexate or placebo plus methotrexate for 52 weeks.
Study: 29338762
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg or 25 mg QW plus methotrexate
Study: 26706043
Drug: l-rhamnose (25.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-rhamnose (25.5 g/d)
Study: 26706043
Drug: inulin (22.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: inulin (22.4 g/d)
Study: 26706043
Drug: control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: control (no supplement)
Study: 17509486
Drug: Rotigotine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine (up to 16 mg/24 h as a transdermal patch)
Study: 17509486
Drug: Pramipexole (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (up to 4.5 mg/day orally)
Study: 16202898
Drug: IV dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV dexmedetomidine (0.5 microg/kg loading dose over 20 minutes, followed by continuous infusion at 0.4 microg/kg/h)
Study: 16202898
Drug: Placebo (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (IV saline at the same calculated loading and infusion rates)
Study: 9568047
Drug: IFN‐alpha treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha treatment
Study: 2652231
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg methysergide
Study: 2652231
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg verapamil
Study: 22188532
Drug: Ruboxistaurin (RBX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruboxistaurin (RBX), 32 mg daily for 8 weeks
Study: 21092474
Drug: α-lipoic acid
Normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-lipoic acid 1800 mg daily for 12 weeks
Study: 19013300
Drug: Leucine plus
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine plus glucose (25 g)
Study: 19201496
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg daily)
Study: 12873924
Drug: Small dose
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small dose lidocaine spinal anesthesia
Study: 29364329
Drug: Comprehensive periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comprehensive periodontal treatment (supra and subgingival scaling and root‐planning and periodontal maintenance appointments)
Study: 29364329
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no comprehensive periodontal treatment)
Study: 26802147
Drug: mapatumumab-sorafenib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: mapatumumab-sorafenib (30 mg/kg on day 1 per 21-day cycle)
Study: 26802147
Drug: placebo-sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo-sorafenib (400 mg, twice daily per 21-day cycle)
Study: 24469903
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with normal daily life
Study: 12070620
Drug: 100%G (maximal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100%G (maximal voluntary contraction for 6 s per set, 12 sets per session)
Study: 12070620
Drug: 60%G (60%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60%G (60% of MVC for 30 s per set, 4 sets per session)
Study: 12070620
Drug: Both 100%G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both 100%G and 60%G
Study: 31274388
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oABI and PWI
Study: 28836279
Drug: Open flap
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open flap debridement without antibiotics (control)
Study: 26785394
Drug: Physiotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy and Occupational Therapy
Study: 26785394
Drug: No Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Therapy
Study: 22827885
Drug: Goal-setting with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-setting with mentoring (goal-setting interview followed by bi-monthly telephone mentoring)
Study: 15450559
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg q12h for 5 doses via suppository, followed by oral 250 mg q8h for 6 doses)
Study: 8166478
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with thoracic radiotherapy
Study: 29016544
Drug: Topical vibration
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical vibration anesthesia during BTX‐A injections
Study: 29016544
Drug: Control side
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control side (BTX‐A injections only)
Study: 19368418
Drug: Eltrombopag 50
Normalized name: eltrombopag 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 50 mg/day
Study: 17299493
Drug: Lycopene supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene supplementation (15 mg/day)
Study: 11571763
Drug: Galantamine 36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine 36 mg/day
Study: 9512200
Drug: Multidose injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidose injection pen
Study: 11204933
Drug: Lacidipine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine (4 mg)
Study: 8148217
Drug: Lacidipine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine (4 mg) and Atenolol (100 mg) co-administration
Study: 1168413
Drug: Alice strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alice strain live attenuated influenza A (H3N2) vaccine
Study: 1168413
Drug: Killed parenteral
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Killed parenteral (KP) bivalent influenza vaccine
Study: 30340960
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral hydration (EOH)
Study: 30340960
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral hydration (COH)
Study: 29310386
Drug: Low viscosity
Normalized name: Gentamicin low viscosity bone cement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low viscosity cement (group L, n = 50)
Study: 23213101
Drug: FOLFIRINOX (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRINOX (oxaliplatin 85 mg/m², irinotecan 180 mg/m², leucovorin 400 mg/m², fluorouracil 400 mg/m² bolus followed by 2400 mg/m² 46-hour continuous infusion, once every 2 weeks)
Study: 23213101
Drug: gemcitabine (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine (1,000 mg/m² weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks)
Study: 19887477
Drug: 1 mg/d
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/d anastrozole
Study: 19887477
Drug: 10 mg/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/wk tamoxifen
Study: 19887477
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of anastrozole and tamoxifen
Study: 16400057
Drug: Soybean ferritin
Normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean ferritin (140 microg Fe as ferritin, 2.5 mg)
Study: 16400057
Drug: FeSO4 (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: FeSO4 (140 microg Fe as FeSO4, 2.5 mg)
Study: 11421999
Drug: Fast infusion
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast infusion of rilmenidine
Study: 11421999
Drug: Slow infusion
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow infusion of rilmenidine
Study: 9347381
Drug: Fluvoxamine-lithium therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine-lithium therapy
Study: 9347381
Drug: Fluvoxamine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine monotherapy
Study: 8482046
Drug: Oral alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alcohol (0.5 g/kg body weight diluted to 300 ml in sugar-free orange juice)
Study: 8482046
Drug: Oral alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alcohol (0.5 g/kg body weight diluted to 300 ml in sugar-free orange juice) during head-up tilt
Study: 3087252
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of cromolyn
Study: 3087252
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of cromolyn
Study: 30587221
Drug: Maintain OAC
Normalized name: mountain pepper whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintain OAC treatment until the day before surgery and resume OAC treatment the day after surgery.
Study: 30587221
Drug: Stop OAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop OAC treatment (with or without low-molecular-weight heparin bridging therapy) according to the anaesthesia guidelines.
Study: 24524222
Drug: Formoterol monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol monotherapy
Study: 22624298
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of iron
Study: 22624298
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of iron in refined palm oil
Study: 22624298
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of iron in palm oil with CTCMC (two doses)
Study: 20171424
Drug: S-amlodipine 5
Normalized name: S-amlodipine
DrugBank: Levamlodipine (DB09237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-amlodipine 5 mg
Study: 20171424
Drug: Amlodipine racemate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine racemate 10 mg
Study: 12521629
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers discontinued
Study: 12521629
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of beta blockers
Study: 12521629
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of beta blockers
Study: 8872324
Drug: Doxorubicin 50
Normalized name: DOXOrubicin 50 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 50 mg/m2 i.v. (VAC)
Study: 8872324
Drug: Mitoxantrone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 10 mg/m2 (VNC)
Study: 31425780
Drug: 0.25% delgocitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% delgocitinib ointment
Study: 31425780
Drug: 0.5% delgocitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% delgocitinib ointment
Study: 26395834
Drug: CT-P13 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P13 (5 mg/kg)
Study: 26795209
Drug: RP (5
Normalized name: Ropinirole
DrugBank: Ropinirole (DB00268)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RP (5 mg/kg)
Study: 15875154
Drug: Simvastatin 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10, 20, 40 mg
Study: 12519867
Drug: Carbenoxolone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone (100 mg every 8 h, orally, for 7 d)
Study: 7751519
Drug: Cetirizine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine therapy
Study: 6626483
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy + medication
Study: 31928076
Drug: IGFBP3 (insulin-like
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGFBP3 (insulin-like growth factor-binding protein 3)
Study: 26978049
Drug: Tenoten children
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoten children (1 tablet 3 times a day for 12 weeks)
Study: 9463203
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml of 2% mepivacaine and 1 ml (30 mg) of ketorolac
Study: 9463203
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml of 2% mepivacaine and 1 ml of saline solution
Study: 9463203
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml of 2% mepivacaine and 1 ml of saline solution plus 30 mg of ketorolac intravenously
Study: 8485325
Drug: Injection sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection sclerotherapy of esophageal varices (Control)
Study: 3446537
Drug: Day case
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day case strabismus surgery without post-operative topical medication
Study: 3446537
Drug: Overnight stay
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overnight stay with topical antibiotic and anti-inflammatory therapy for 14 days
Study: 22929730
Drug: Low-dose dexmedetomidine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexmedetomidine (target = 0.15 ng/ml plasma)
Study: 14520131
Drug: Gabapentin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (400 mg qid)
Study: 11105733
Drug: Herbal and
Normalized name: ALLANTOIN 1 g in 100 g TOPICAL CREAM [Scar Reducer Intensive Herbal and Nutrient]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal and over-the-counter antidepressants
Study: 1558003
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment for ISH
Study: 3891285
Drug: Filtered amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Filtered amphotericin B infusions (1 micron filter)
Study: 3891285
Drug: Unfiltered amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfiltered amphotericin B infusions
Study: 29164960
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 0.05% cream plus emollient (Group A)
Study: 27470152
Drug: Cefazolin 2
Normalized name: cefazolin 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 2 g intravenously 30 minutes prior to the procedure (n = 91)
Study: 18680228
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg daily for 3 years)
Study: 8905278
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose fentanyl/midazolam anesthesia
Study: 8905278
Drug: Thoracolumbar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracolumbar epidural blockade with high dose fentanyl/midazolam anesthesia
Study: 6410898
Drug: 1 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/kg ideal body weight amino acid infusion
Study: 6410898
Drug: 2 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/kg ideal body weight amino acid infusion
Study: 24107112
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg naltrexone (high-dosage group)
Study: 24107112
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg naltrexone (low-dosage group)
Study: 24107112
Drug: Injectable depot
Normalized name: methylprednisolone Injection [Depo-Medrol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable depot naltrexone (400 mg)
Study: 20622475
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment (at least 5 days before operation)
Study: 15138760
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 0.3 mg/kg acute dose
Study: 15138760
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 0.6 mg/kg acute dose
Study: 15138760
Drug: Chronic Methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic Methylphenidate administration
Study: 12243813
Drug: Oxaliplatin (OXA)
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin (OXA) 25 mg/m²/day in 30-min infusions, bolus leucovorin (LV) 20 mg/m²/day, bolus 5-FU 375 mg/m²/day, given on 4 days during Weeks 1 and 5 of radiotherapy (50.4 Gy). A single OXA dose (50 mg/m²) was given on the third week of radiotherapy.
Study: 11165426
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with exposure therapy in a group context
Study: 11165426
Drug: Comparison treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison treatment avoiding trauma focus
Study: 27214168
Drug: ABCT (Alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABCT (Alcohol Behavioral Couple Therapy)
Study: 20035583
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 20-70 mg/day
Study: 20384496
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of 7-valent PCV (PCV7) at ages 4 and 6 months
Study: 20384496
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of 7-valent PCV (PCV7) at ages 2, 4, and 6 months
Study: 20384496
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of PCV7 at age 12 months
Study: 12971419
Drug: Protocol A
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A (three equal, divided doses given with meals over 10 h)
Study: 12971419
Drug: Protocol B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol B (three equal doses over 14 h)
Study: 12971419
Drug: Protocol C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol C (four equal doses over 14 h)
Study: 12971419
Drug: Protocol D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol D (six equal doses over 24 h)
Study: 10480516
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (0.2 U/kg)
Study: 10480516
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin (0.2 U/kg)
Study: 8917741
Drug: ApoCIII genotype
Normalized name: AKCEA-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ApoCIII genotype CC
Study: 24510496
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g twice daily of creatine monohydrate
Study: 22237819
Drug: modified Story
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified Story Memory Technique (mSMT) treatment (n = 8)
Study: 20064185
Drug: MAL PDT
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAL PDT (methyl aminolevulinate) applied as cream 160 mg/g for 3 hours, followed by illumination with broad-spectrum red light (75 J/cm², 570-670 nm), repeated 7 days later.
Study: 20064185
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied for 3 hours, followed by illumination with broad-spectrum red light (75 J/cm², 570-670 nm), repeated 7 days later.
Study: 12182270
Drug: Cognitive-Processing Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Processing Therapy (CPT)
Study: 9696367
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HD-MTX) consolidation and reintensification
Study: 9696367
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of multidrug induction, HD-MTX consolidation, and reintensification
Study: 9696367
Drug: Conventional doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional doses of methotrexate
Study: 9696367
Drug: Short intensive
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short intensive chemotherapy pulses including HD-MTX
Study: 23265705
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CRT) and lapatinib followed by lapatinib
Study: 23265705
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CRT) and placebo followed by placebo
Study: 17084249
Drug: Torcetrapib 90
Normalized name: Torcetrapib
DrugBank: Torcetrapib (DB06281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torcetrapib 90 mg/day
Study: 17084249
Drug: Torcetrapib 60
Normalized name: Torcetrapib
DrugBank: Torcetrapib (DB06281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torcetrapib 60 mg/day